Merck is a massive company with strong fundamentals and underlying value at a heavily discounted price. Click here to find ...

Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically ...

Merck’s MRK blockbuster PD-L1 inhibitor, Keytruda, approved for several types of cancer indications, is the company's biggest ...

Summit Therapeutics (NASDAQ:SMMT) shares spiked on Thursday, triggering a trading halt after Bloomberg News reported that ...

Merck's growing pipeline, with nearly 20 new launches ahead, is set to reshape its portfolio as Keytruda's 2028 patent expiry ...

Merck has received approval from the Food and Drug Administration to expand use of its blockbuster drug, Keytruda, to treat head and neck cancers.

It boasts more than 80 programs in phase 2 or phase 3 studies. Even with a 25% success rate for these, that should translate ...

Merck MRK has reached a significant support level, making it an attractive option for investors from a technical standpoint. Since early June, the stock has broken through its 50-day simple moving ...

Merck said last week its biggest tariff exposure is through Keytruda and it has enough US inventory for this year. It estimated $200 million in additional costs for the levies implemented to date.

Merck's Keytruda receives FDA approval for head and neck cancer after showing improved event-free survival in Phase 3 KEYNOTE-689 trial.

Merck & Co., Inc. (NYSE:MRK) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company shared ...